THE-UNNAMED-SOCIETY
25.10.2021 10:32:07 CEST | Business Wire | Press release
Following through on its unique reinterpretation of Pancho Villa’s Bisley Colt introduced in 2019, The Unnamed Society takes the natural next step with Golden Boy , a reimagination of the legendary Winchester repeating rifle.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005046/en/
Golden Boy is a work of art in form and function that adds a new dimension to a story that remains as fascinating and inspiring as ever, that of the Wild West and how it was won.
A true-to-the-legend reimagination of the iconic lever action rifle as a clock, its original loading and cocking mechanism rethought for winding the timekeeping calibre and setting the time. Holding – and beholding – this uniquely fascinating feat of engineering and artisanship evokes childhood dreams of a far-away age that ultimately helped shape our modern times. It can be displayed to great effect both on a desk, mantelpiece or on the wall.
Golden Boy doesn’t just tell time, but opens our imagination and takes us to where the buffalo once roamed and brave men and women struck out into the unknown, stood their ground and built a new world.
Today, the partnership between The Unnamed Society and the watch company l’Epée 1839 opens the second chapter of its unfolding history. With Golden Boy comes the second stunning creation imagined for those who set the bar for the Art of Gifting a bit higher than the rest.
Nicknamed the ‘Gun that Won the West,’ the Winchester Rifle remains one of the most iconic firearms of all time. For the gun that inspired Golden Boy , the year is 1866. It has the same dimensions and weight as the original, the same feel and heft.
Able to hold 15 rounds before having to reload, the original was not only much more practical than a single-shot rifle, but also allowed for excellent handling and accuracy without any significant training.
The watchmaker captures this defining movement of the hand as it loads the round and prepares the gun for firing: by having the clock mechanism wound – ‘loaded’ – in exactly the same way. By actioning the lever 15 times – as if loading 15 bullets one after the other – the mechanism is fully wound for a 7-day power reserve.
If marvel at the heart of each Golden Boy is only matched by the fact that it only comes as a bespoke creation, completely finished to the owner’s wishes. For the receiver, barrel and tubular magazine, the owner can choose from steel, 18K yellow, rose or white gold, and palladium. For the stock and forestock, from a selection of exotic woods.
Press Material: TUSSIAR2021 - Google Drive
View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005046/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
